Breaking the Tyranny of Treatment: A New Perspective on Alzheimer’s Care
Related posts:
- FDA Approves Donanemab Today, the US Food and Drug Administration granted full clinical approval to Eli Lilly to market donanemab, brand name KISUNLA, for the treatment of early Alzheimer’s disease, including Mild Cognitive Impairment (MCI) or mild dementia. Donanemab is a monoclonal antibody against the beta-amyloid protein that accumulates in the brain of...
- Keeping sleep in mind: poor sleep and dementia risk A recent article in the New York Times, How Poor Sleep Affects Your Risk of Dementia, summarizes some recent findings showing both excessively short and long sleep, as well as sleep disorders such as sleep apnea, insomnia, and rapid-eye movement (REM) behavior disorder, may be linked with risk for Alzheimer’s...
